Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

被引：39
作者：
van der Kooij, M. K. [1 ]
Joosse, A. [1 ]
Speetjens, F. M. [1 ]
Hospers, G. A. P. [2 ]
Bisschop, C. [2 ]
de Groot, J. W. B. [3 ]
Koornstra, R. [4 ]
Blank, C. U. [5 ]
Kapiteijn, E. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Clin Oncol, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands
[3] Isala, Dept Med Oncol, Zwolle, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[5] Netherlands Canc Inst NKI AVL, Dept Med Oncol, Amsterdam, Netherlands
来源：
ACTA ONCOLOGICA | 2017年 / 56卷 / 01期
关键词：
IPILIMUMAB; TRIAL;
D O I：
10.1080/0284186X.2016.1260773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：101 / 103
页数：3
相关论文
共 50 条
  • [41] Pembrolizumab as first-line treatment for metastatic uveal melanoma
    Rossi, Ernesto
    Pagliara, Monica Maria
    Orteschi, Daniela
    Dosa, Tommaso
    Sammarco, Maria Grazia
    Caputo, Carmela Grazia
    Petrone, Gianluigi
    Rindi, Guido
    Zollino, Marcella
    Blasi, Maria Antonietta
    Cassano, Alessandra
    Bria, Emilio
    Tortora, Giampaolo
    Schinzari, Giovanni
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (07) : 1179 - 1185
  • [42] The safety of anti PD-1 therapeutics for the treatment of melanoma
    Ramelyte, Egle
    Schindler, Sabrina A.
    Dummer, Reinhard
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (01) : 41 - 53
  • [43] Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
    Kambayashi, Yumi
    Fujimura, Taku
    Hidaka, Takanori
    Aiba, Setsuya
    FRONTIERS IN MEDICINE, 2019, 6
  • [44] Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
    Nakamura, Y.
    Namikawa, K.
    Yoshino, K.
    Yoshikawa, S.
    Uchi, H.
    Goto, K.
    Fukushima, S.
    Kiniwa, Y.
    Takenouchi, T.
    Uhara, H.
    Kawai, T.
    Hatta, N.
    Funakoshi, T.
    Teramoto, Y.
    Otsuka, A.
    Doi, H.
    Ogata, D.
    Matsushita, S.
    Isei, T.
    Hayashi, T.
    Shibayama, Y.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1198 - 1206
  • [45] Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
    Rose, April A. N.
    Armstrong, Susan M.
    Hogg, David
    Butler, Marcus O.
    Saibil, Samuel D.
    Arteaga, Diana P.
    Muniz, Thiago Pimentel
    Kelly, Deirdre
    Ghazarian, Danny
    King, Ian
    Kamil, Zaid Saeed
    Ross, Kendra
    Spreafico, Anna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
  • [46] Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease
    Maul, Lara V.
    Weichenthal, Michael
    Kaehler, Katharina C.
    Hauschild, Axel
    JOURNAL OF IMMUNOTHERAPY, 2016, 39 (04) : 188 - 190
  • [47] Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
    Ascierto, Paolo A.
    Capone, Mariaelena
    Grimaldi, Antonio M.
    Mallardo, Domenico
    Simeone, Ester
    Madonna, Gabriele
    Roder, Heinrich
    Meyer, Krista
    Asmellash, Senait
    Oliveira, Carlos
    Roder, Joanna
    Grigorieva, Julia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [48] Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit
    Patel, Anisha B.
    Farooq, Sahira
    Welborn, Macartney
    Amaria, Rodabe N.
    Chon, Susan Y.
    Diab, Adi
    Oliva, Isabella C. Glitza
    Huen, Auris O.
    Li, Shirley Q.
    Nelson, Kelly C.
    Pacha, Omar
    Patel, Sapna P.
    Rapini, Ronald P.
    Tawbi, Hussein A.
    Wong, Michael K.
    McQuade, Jennifer
    Davies, Michael A.
    Haydu, Lauren E.
    CANCER, 2022, 128 (05) : 975 - 983
  • [49] The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
    Uryvaev, Anton
    Passhak, Maria
    Hershkovits, Dov
    Sabo, Edmond
    Bar-Sela, Gil
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [50] Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients
    Heidelberger, Valentine
    Goldwasser, Francois
    Kramkimel, Nora
    Jouinot, Anne
    Huillard, Olivier
    Boudou-Rouquette, Pascaline
    Chanal, Johan
    Arrondeau, Jennifer
    Franck, Nathalie
    Alexandre, Jerome
    Blanchet, Benoit
    Leroy, Karen
    Avril, Marie-Francoise
    Dupin, Nicolas
    Aractingi, Selim
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 436 - 441
12345